Lexicon Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Lexicon PharmaceuticalsDie Erträge des Sektors -22.8% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Biotechs growing auf 17.4% pro Jahr stiegen. Die Einnahmen sind declining mit einer durchschnittlichen Rate von 53.9% pro Jahr gesunken.

Key information

-33.1%

Earnings growth rate

-21.9%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-61.8%
Return on equity	-190.2%
Net Margin	-14,710.9%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Mar 12

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Jan 26

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Jul 13

Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug

Jun 29

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Jun 15

Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

May 31

Revenue & Expenses Breakdown
Beta

How Lexicon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:LXRX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	1	-177	114
30 Sep 23	1	-158	98
30 Jun 23	0	-131	78
31 Mar 23	0	-110	59
31 Dec 22	0	-102	48
30 Sep 22	0	-97	41
30 Jun 22	0	-97	35
31 Mar 22	0	-90	33
31 Dec 21	0	-88	32
30 Sep 21	0	-68	30
30 Jun 21	7	38	32
31 Mar 21	16	-13	38
31 Dec 20	24	-59	44
30 Sep 20	33	-104	52
30 Jun 20	320	39	57
31 Mar 20	321	85	57
31 Dec 19	322	130	57
30 Sep 19	330	164	59
30 Jun 19	43	-89	61
31 Mar 19	47	-101	63
31 Dec 18	63	-121	64
30 Sep 18	81	-126	63
30 Jun 18	101	-129	64
31 Mar 18	99	-130	66
31 Dec 17	92	-123	66
30 Sep 17	80	-133	64
30 Jun 17	81	-138	60
31 Mar 17	89	-141	50
31 Dec 16	79	-131	43
30 Sep 16	188	-22	36
30 Jun 16	160	-22	29
31 Mar 16	141	-11	27
31 Dec 15	130	-5	24
30 Sep 15	24	-94	21
30 Jun 15	24	-100	21
31 Mar 15	24	-98	19
31 Dec 14	23	-100	19
30 Sep 14	3	-115	19
30 Jun 14	3	-106	19
31 Mar 14	2	-109	18
31 Dec 13	2	-104	17
30 Sep 13	1	-112	18
30 Jun 13	1	-109	17

Qualität der Erträge: LXRX ist derzeit unrentabel.

Wachsende Gewinnspanne: LXRX ist derzeit unrentabel.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Ergebnisentwicklung: LXRX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 22.8% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von LXRX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: LXRX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-42.7%) erschwert.

Return on Equity

Hohe Eigenkapitalrendite: LXRX hat eine negative Eigenkapitalrendite (-113.15%), da es derzeit unrentabel ist.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Lexicon Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

Price target decreased to US$8.00

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. Announces New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

Lexicon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Lexicon Phmaceuticals, Inc. Announces That New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events

Lexicon Pharma: Key Regulatory Event In May 2023

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Lexicon Pharmaceuticals, Inc. Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

Lexicon announces FDA review of heart failure therapy

Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Price target increased to US$12.50

Lexicon Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 2 Proof-Of-Concept Study of Lx9211 in Painful Diabetic Neuropathy

Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus forecasts updated

Lexicon Pharmaceuticals, Inc. Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

Consensus revenue estimates fall by 99%

Revenue & Expenses Breakdown
Beta